As medical experts question the efficacy of mammograms in breast cancer screening, a new study shows that computer-aided detection technology used during the process does not help spot cancer in patients.
Startup Delphinus Medical Technologies has raised $39.5 million to support a pivotal trial of its ultrasound breast cancer system, SoftVue. The system enables the imaging of the entire breast including the chest wall and is expected to be more effective at identifying tumors in dense breasts--without creating a high false positive rate.
Researchers have long searched for ways to track cancer cells as they proliferate and stop them from spreading. Now, scientists in the U.S. are developing a spongelike device that can mop up cancer cells as they move through the body, potentially offering an early warning sign to doctors.
The oncology community is divided over intraoperative radiation therapy, which as its name suggests is given at the same time as lumpectomy to breast cancer patients.
As med tech companies roll out innovative radiation devices to treat breast cancer, medical experts are debating the pros and cons of a new technique that could be less expensive and more convenient than traditional therapy for the disease.
Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed.
A new biomarker for lethal cases of basal-like breast cancer (BLBC) could provide a new and more precise target for cancer drug developers. Researchers at Boston University say they found that a molecule named IL13RA2 (IL13R alpha2) is found clustered on the surface of BLBC cells among late-stage and metastatic cases, when the disease is almost impossible to slow down.
As physicians turn to mammography as a more reliable way to diagnose breast cancer, a new study shows that the screening method does not reduce the number of deaths from the disease and could lead to overdiagnosis, suggesting a few kinks in the system.
Dalantercept (ACE-041) is owned by Acceleron and is currently in early clinical trials for liver and kidney carcinomas. More recently, though, researchers at Lund University demonstrated that it could block the activin receptor-like 1 (ALK1) pathway, suggesting it may also slow metastasis in aggressive breast cancer.
Scientists from Cincinnati Children's Hospital Medical Center report that the best way to prevent breast cancer from growing resistant to therapies may be to genetically strip cancer cells' natural defenses against intrinsic stress.